Lung Cancer: Clinical Trial Overview

Lung Cancer:
Clinical Trial
Overview
Info@ISRreports.com

©2014 Industry Standard Research www.ISRreports.com
PREVIEW

www.ISRreports.com ©2014 | Preview of: Lung Cancer: Clinical Trial Overview 2
act with confidence
Report Introduction:
This report provides insight into the current clinical trial activity surrounding lung cancer by examining
industry-sponsored activities and quantifying important development milestones and trial metrics:
• Phase of study
• Study type distribution (expanded access, interventional, observational)
• Length of trials
• Patient enrollment
• Study sponsors
• Regional breakdown
41
Pages
Q2, 2014
Publication Date
33
Charts and Graphs
Major Sections:
How you can use this report:
1. Introduction
2. Lung Cancer Clinical Trial Analysis
3. Average Clinical Trial Enrollment
4. Study Sponsor Analysis by Phase
5. Regional Analysis
• Identify how products currently in development could impact this market and understand competitor
involvement by using detailed information on current late phase lung cancer trials
• Benchmark your study length and patient enrollment metrics against industry-wide, phase-specific,
and study type-specific averages
• Plan your clinical trial strategy better by understanding where industry-funded lung cancer trial sites
are located globally
NEXT: Sponsors Included

act with confidence
• Actavis
• Agennix
• American College of Radiology
• Amgen
• AstraZeneca
• Betta Pharmaceuticals
• Biocad
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene Corporation
• Cell Therapeutics
• Cell>Point
• Chong Kun Dang Pharmaceutical
• Eisai
• Eli Lilly and Company
• EMD Serono
• Genentech
• Gilead Sciences
• GlaxoSmithKline
• Helsinn Therapeutics (U.S.)
• Hoffmann-La Roche
• InSightec
• J. Uriach and Company
• Janssen Korea
• Jiangsu HengRui Medicine Co.
• Kael-GemVax Co.
• MedImmune
• Merck KGaA
• Neomend
• Novartis Pharmaceuticals
• Peregrine Pharmaceuticals
• Pfizer
• Pierre Fabre Pharma GmbH
• Sanofi
• Swami Rama Cancer Hospital and Research
Institute
• Synta Pharmaceuticals
• Teva Pharmaceutical Industries
• Veran Medical Technologies
• Yantai Medgenn
Sponsors Included:

act with confidence
Table of Contents
For full table of contents and additional sample pages, download the full preview
from our website:
http://www.isrreports.com/product/lung-cancer-clinical-trial-overview/

act with confidence
act with confidence
Introduction
www.ISRreports.com ©2014 | Lung Cancer: Clinical Trial Overview 7
Overview
Lung cancer is one of the most destructive, difficult to detect, and deadly forms of
cancer� There are two distinct forms of lung cancer: small-cell and non-small cell lung
cancer� Roughly 80% of all lung cancer cases are non-small cell lung cancer� Often,
both small cell and non-small cell lung cancer will spread to other parts of the body� In
addition to the risk of lung cancer spreading, it is also very difficult to detect in its earliest
stages since there are often no symptoms until the cancer is highly advanced�
Though lung cancer is often associated with cigarette smoking, there are multiple
causes including radon exposure, industrial exposures, and genetic factors� The
number of different causes for lung cancer leads to difficulty in diagnosis and
treatment� Imaging tests such as CT, PET and bone scans are the primary means
by which the threat of lung cancer is identified� Bronchoscopies, ultrasounds,
mediastinoscopies, mediastinotomies, thoracentesis, thoracoscopies, sputum
cytology, and fine needle biopsies are then often used to actually diagnose the cancer�
Clinical trials play a consistent role in the treatment of lung cancer since there is no de
facto standard procedure or therapy used to rid patients of the disease� New drugs,
therapies and medical devices are constantly being introduced to the clinical stages of
development�
This report reviews the current clinical trial activity surrounding lung cancer�
Specifically, ISR has examined those clinical trial studies that “Industry” has helped
fund� www�clinicaltrials�gov allows the sorting of studies based on the “funder type”
with the following options: NIH, Industry, Other U�S Federal Agency, and All Others
(Individual, University, Organization, …)� This report focuses only on those studies
that have listed “Industry” as the funder type� A number of data points relating to lung
cancer clinical trials are outlined in detail in the following sections of this report:
• Phase of study
• Study type distribution (expanded access, interventional, observational)
• Length of trails
• Patient enrollment
• Regional breakdown
Sample Page

act with confidence
act with confidence
Introduction
www.ISRreports.com ©2014 | Lung Cancer: Clinical Trial Overview 6
Lung cancer claims more
lives each year than do
colon, prostate, ovarian and
breast cancers combined.
39,620
Breast Cancer
50,310
Colon Cancer
14,270
Ovarian Cancer
159,260Lung Cancer
ONE IN 14 PEOPLEWILL DEVELOP LUNG CANCER.
DEATHS PER YEAR
TREATMENT
2/3 OF PEOPLE WITH
LUNG CANCER ARE
DIAGNOSED AT AGE 65
OR OLDER
AT LEAST 80% OF LUNG
CANCER DEATHS ARE
THOUGHT TO RESULT
FROM SMOKING.
For stage I and II, surgery remains the primary
treatment . Patients often undergo either
radiation therapy, systemic chemotherapy,
molecular-targeted therapy, stage-based
management or a combination of these.
+ +
LUNG
CANCERIS THE
LEADING CAUSE OF
CANCER DEATH.
Sources: ISR Reports, cancer�org, cancer�gov, mayoclinic�org, dailyinfographic�org
Sample Page

act with confidence
Sample Page
For full table of contents and additional sample pages, download the full preview
from our website:

act with confidence
Ordering Information
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services indus-
tries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.

For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at
www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
About Industry Standard Research
Save on this,
or any ISR
report, by
registering a
free account
Register now
• Receive a $250 instant credit towards any ISR report
• Earn 10% credit towards all future purchases
• Receive advanced notifications on ISR’s latest reports and free resources
For pricing and ordering information, please visit our website:

act with confidence
www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 9
act with confidence
The ISR Difference
Custom-quality syndicated market research
www.ISRreports.com
ISR's Reports
The Common
Syndicated Reportvs.
How confident are you?
vs.
DataCollection
ISR's proprietary data collection
tools and channels support fast,
high quality data collection
Struggle to recruit the right
targets and enough of them
vs.
SampleSizes
Robust sample sizes that
instill confidence
Often insufficient industry
representation that leaves you
defending results
vs.
Research methods
Mostly primary
research;
always appropriate
for the topic
One size fits all;
usually publically
available data
vs.vs.
Respondents
Sophisticated screening
ensures genuine
decision-makers
Undisclosed
methodologies and
respondent demographics
vs.vs.
Analysts
Decades of experience
means more insights that are
immediately usable
Junior analysts capable of
reporting numbers

Lung Cancer: Clinical Trial Overview

Recommandé

Recommandé

Contenu connexe

En vedette

En vedette (12)

Plus de Industry Standard Research

Plus de Industry Standard Research (20)

Dernier

Dernier (20)

Lung Cancer: Clinical Trial Overview